Cargando…
Tranexamic acid for haemostasis and beyond: does dose matter?
Tranexamic acid (TXA) is a widely used antifibrinolytic agent that has been used since the 1960’s to reduce blood loss in various conditions. TXA is a lysine analogue that competes for the lysine binding sites in plasminogen and tissue-type plasminogen activator impairing its interaction with the ex...
Autores principales: | Lam, Tammy, Medcalf, Robert L., Cloud, Geoffrey C., Myles, Paul S., Keragala, Charithani B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496216/ https://www.ncbi.nlm.nih.gov/pubmed/37700271 http://dx.doi.org/10.1186/s12959-023-00540-0 |
Ejemplares similares
-
Tranexamic acid in a mouse model of cerebral amyloid angiopathy: setting the stage for a novel stroke treatment approach
por: Liu, Zikou, et al.
Publicado: (2023) -
Tranexamic acid alters the immunophenotype of phagocytes after lower limb surgery
por: Draxler, Dominik F., et al.
Publicado: (2022) -
Fibrinolysis: A Primordial System Linked to the Immune Response
por: Medcalf, Robert L., et al.
Publicado: (2021) -
The Fibrinolytic System: Mysteries and Opportunities
por: Medcalf, Robert L., et al.
Publicado: (2021) -
t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke
por: Draxler, Dominik F., et al.
Publicado: (2019)